Janux impresses again
The company reports an “unprecedented” 100% PSA50 rate with JANX007, but in a small, selected number of patients.
Roche doubles down on Poseida
A $1bn buyout gives Roche more allogeneic Car-T projects, plus non-viral gene therapy contenders.
Regeneron gets another bispecific blow
Meanwhile, recent updates hint at more issues in the group’s pipeline of bispecific MAbs.
Telix heads to the US, as RayzeBio runs into problems
Supply continues to cause headaches for radiopharmaceutical developers.
FibroGen throws down the prostate cancer gauntlet
Amid doubts about early data with FG-3246, the group is scathing about its rivals.
Deal analysis part three – the undecided
Of the big oncology deals since 2016, there are still plenty that could go either way.
Janux gives conditionally acting therapeutics hope
Early activity of JANX007 in prostate cancer sees Janux stock gain 190%.
Deal analysis part two – the good
A look at big oncology deals since 2016 finds outright success stories hard to come by.
